Form 4: Oscar Health's President of Technology & CTO, Mario Schlosser, Reports Stock Sales
SEC Form 4
Mario Schlosser, President of Technology & CTO of Oscar Health, Inc., reports the sale of Class A Common Stock to cover tax obligations related to vesting equity awards.
Summary
- Mario Schlosser, the President of Technology & CTO of Oscar Health, Inc., filed a Form 4 detailing changes in beneficial ownership.
- On September 1, 2024, 14,412 restricted stock units vested and were converted into Class A Common Stock.
- Schlosser sold 3,198 shares on September 3, 2024, at an average price of $17.99.
- Additional sales occurred on September 4, 2024, with 1,605 shares sold at an average price of $17.46 and 1,311 shares sold at an average price of $17.85.
- These sales were executed under a pre-existing Rule 10b5-1 trading plan to cover tax withholding obligations.
- Following these transactions, Schlosser directly owns 74,066 shares of Class A Common Stock and 144,117 restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports stock sales by an executive under a pre-existing plan for tax obligations. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Positives
- The sales were conducted under a pre-existing Rule 10b5-1 trading plan, which is often viewed as a structured and transparent approach to selling shares.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, although in this case, it's attributed to tax obligations.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies. Monitoring these transactions provides insights into management's perspective on the company's value and financial health. Rule 10b5-1 plans are frequently used to avoid accusations of insider trading.
Stakeholder Impact
- The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely minimal given the structured nature of the sales.
Key Dates
| Date | Description |
|---|---|
| February 27, 2023 | Date prior to which the Rule 10b5-1 instruction letter was entered into. |
| June 1, 2024 | Start date for the vesting of restricted stock units in 12 equal quarterly installments. |
| September 1, 2024 | Date of restricted stock unit vesting. |
| September 3, 2024 | Date of first reported stock sale. |
| September 4, 2024 | Date of subsequent stock sales. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.